These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Synthesis and pharmacological evaluation of 99mTc-labeled imidazolyl-containing diphosphonic acid as a novel bone imaging agent.
    Author: Qiu L, Cheng W, Lin J, Zhang S, Luo S.
    Journal: J Labelled Comp Radiopharm; 2013 Sep; 56(11):573-80. PubMed ID: 24285189.
    Abstract:
    In order to develop a superior bone imaging agent, a new radiotracer (99m)Tc-1-hydroxy-5-(2-butyl-1H-imidazol-1-yl)pentane-1,1-diyldiphosphonic acid (BIPeDP) was designed and prepared with good radiochemical yield and stability. The biodistribution in mice shows that (99m)Tc-BIPeDP has high specificity in the skeleton with the maximum uptake of 17.30 ± 0.14 injected dose per gram at 60 min. Kinetics of blood clearance shows that the distribution half-life (T1/2α) and elimination half-life (T1/2β) of (99m)Tc-BIPeDP are 3.7 and 49.7 min, respectively. An excellent image can be obtained at 1-h post-injection with the single photon emission computed tomography bone scanning, which is clearer and quicker than (99m)Tc-zoledronic acid, (99m)Tc-1-hydroxy-5-(1H-imidazol-1-yl)pentane-1,1-diyldiphosphonic acid, and (99m)Tc-methylenediphosphonic acid All results indicate that (99m)Tc-BIPeDP holds great potential as a novel promising bone imaging agent.
    [Abstract] [Full Text] [Related] [New Search]